Changes in Hong Kong stocks | Kaituo Pharmaceutical-B (09939) rose more than 7%, successfully completed the KT-939 long-term human safety test and is actively promoting related registration applications

The Zhitong Finance App learned that Kaituo Pharmaceutical-B (09939) rose by more than 7%. As of press release, it had risen 7.14% to HK$1.95, with a turnover of HK$1.120,600.

According to the news, Kaituo Pharmaceutical-B announced that its self-developed long-term human safety test for KT-939, a novel high-efficiency tyrosinase inhibitor that inhibits melanin production, was successfully completed on September 4, 2026. After a total of 114 subjects used KT-939 for 52 consecutive weeks, preliminary data showed that there were no adverse skin reactions, and clinical use results for 28 weeks in the middle of the trial were consistent, fully demonstrating that KT-939 has good safety.

As a next-generation innovative whitening and freckle removal ingredient, KT-939 needs to be registered and approved by the State Drug Administration before it can be marketed. This long-term safety test was completed in accordance with the guidelines on the “Human Long-term Trial Test Method” for cosmetic ingredients issued by the Drug Administration on June 18, 2026. The results are one of the most important components of the KT-939 registration application data. The company is actively promoting the registration application process for KT-939. After obtaining the results of this long-term safety test, it plans to complete the submission of all application materials to the Drug Administration as soon as possible.